Lead Product(s): Probiotic
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Timberline Holdings
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 29, 2021
ResBiotic’s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal’s Pulmonary Microbiome Lab at UAB with research and expertise from the university’s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development program.